Search research articles
Contact Us
Filters
Showing results (111-120 of 131) with videos related to
Page
of 14
Sort By:
Acta Anaesthesiologica Scandinavica
|
November 26, 2008
Impaired myocardial t-PA release in patients with coronary artery disease
B Osterlund, S Jern, C Jern, et al.
Acta Anaesthesiologica Scandinavica
|
November 21, 1997
Aortic cross-clamping influences regional net release and uptake rates of tissue-type plasminogen activator in pigs
H Seeman-Lodding, S Häggmark, C Jern, et al.
Acta Anaesthesiologica Scandinavica
|
July 17, 1999
Systemic levels and preportal organ release of tissue-type plasminogen activator are enhanced by PEEP in the pig
H Seeman-Lodding, S Häggmark, C Jern, et al.
Hypertension (Dallas, Tex. : 1979)
|
November 18, 2000
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators
P M Okin, R B Devereux, S Jern, et al.
American Journal of Hypertension
|
August 11, 2001
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study
P M Okin, R B Devereux, S Jern, et al.
Acta Anaesthesiologica Scandinavica. Supplementum
|
January 1, 1997
Anesthesia and surgery influences regional net release and uptake rates of tissue-type plasminogen activator. An experimental study in the intact pig
H Seeman-Lodding, B Biber, S Häggmark, et al.
Nordisk Medicin
|
January 1, 1983
[Review of new pharmacological treatment principles in hypertension]
L Andrén, B Dahlöf, R Eggertsen, et al.
Journal of Cardiovascular Pharmacology
|
January 1, 1991
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group
S Jern, L Hansson, B Scherstén, et al.
Journal of Cardiovascular Pharmacology
|
January 1, 1987
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension
B Dahlöf, L Andrén, R Eggertsen, et al.
Lakartidningen
|
March 9, 1983
[A review of recent pharmacological therapeutic principles in hypertension]
L Andrén, B Dahlöf, R Eggertsen, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 131) with videos related to
Sort By:
Page
of 14
Acta Anaesthesiologica Scandinavica
|
November 26, 2008
Impaired myocardial t-PA release in patients with coronary artery disease
B Osterlund, S Jern, C Jern, et al.
Acta Anaesthesiologica Scandinavica
|
November 21, 1997
Aortic cross-clamping influences regional net release and uptake rates of tissue-type plasminogen activator in pigs
H Seeman-Lodding, S Häggmark, C Jern, et al.
Acta Anaesthesiologica Scandinavica
|
July 17, 1999
Systemic levels and preportal organ release of tissue-type plasminogen activator are enhanced by PEEP in the pig
H Seeman-Lodding, S Häggmark, C Jern, et al.
Hypertension (Dallas, Tex. : 1979)
|
November 18, 2000
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators
P M Okin, R B Devereux, S Jern, et al.
American Journal of Hypertension
|
August 11, 2001
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study
P M Okin, R B Devereux, S Jern, et al.
Acta Anaesthesiologica Scandinavica. Supplementum
|
January 1, 1997
Anesthesia and surgery influences regional net release and uptake rates of tissue-type plasminogen activator. An experimental study in the intact pig
H Seeman-Lodding, B Biber, S Häggmark, et al.
Nordisk Medicin
|
January 1, 1983
[Review of new pharmacological treatment principles in hypertension]
L Andrén, B Dahlöf, R Eggertsen, et al.
Journal of Cardiovascular Pharmacology
|
January 1, 1991
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group
S Jern, L Hansson, B Scherstén, et al.
Journal of Cardiovascular Pharmacology
|
January 1, 1987
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension
B Dahlöf, L Andrén, R Eggertsen, et al.
Lakartidningen
|
March 9, 1983
[A review of recent pharmacological therapeutic principles in hypertension]
L Andrén, B Dahlöf, R Eggertsen, et al.
Page
of 14